Navigation Links
Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial
Date:1/27/2009

14.3%) for the control arm, p = 0.003). PFS, CR/CRu and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.

The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised.

The EXTEND clinical trial is a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician. The trial was designed to examine the complete remission or unconfirmed complete remission rate, overall survival and progression-free survival. The study received Special Protocol Assessment approval from the FDA in 2004 and pixantrone has received fast track designation for this indication.

The Company announced on January 27, 2009 that after a pre-NDA communication with the FDA, it expects to begin submission of a rolling NDA and request priority review for pixantrone to treat relapsed aggressive NHL in the first quarter of 2009.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracycl
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. Demand for VScan Dengue Fever Test Kits Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Feb. 10, 2011 ,We are in a State of ... message that concerned Florida residents are desperate for people to hear. ... day due to prescription drug abuse and statistics show it is ... (FAADA) is calling for an immediate Congressional hearing to help put ...
... Feb. 10, 2011 For the biopharmaceutical industry, ... - and difficulty - of interacting with patients ... have created both opportunities and challenges for approaching ... To help marketing teams in the ...
Cached Medicine Technology:Parents, Physicians Unite and Declare: State of Emergency 2Parents, Physicians Unite and Declare: State of Emergency 3Innovations in Patient-Focused Initiatives to Improve Outcomes 2
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
(Date:4/17/2014)... by researchers at UC Davis has shown that the ... in cell division, also boosts the mitochondrial activity to ... complex has been shown to perform both jobs. This ... to control cellular energy production, potentially advancing cancer care ... in the journal Developmental Cell . , "These ...
(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...
(Date:4/17/2014)... improves general blood flow and alleviates muscle soreness ... at the University of Illinois at Chicago. , ... in the Archives of Physical Medicine and ... function in people who had not exercised, suggesting ... their level of physical activity. , Improved circulation ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2
... are one of the most common health problems for children, ... birthday. Annual costs in the United States alone are in ... are left untreated, complications can include hearing loss, speech problems ... brain, causing meningitis. But not all kids have the same ...
... By Madonna Behen HealthDay Reporter , MONDAY, Oct. ... can be equally sleep-deprived, and yet the next day one ... other? The answer could be in their genes, a ... School of Medicine found that healthy individuals who test positive ...
... HealthDay Reporter , MONDAY, Oct. 25 (HealthDay News) -- One ... -- may cut the risk of dying for men who ... gland, a new study suggests. In looking at the ... of whom were taking aspirin or another blood-thinning drug, researchers ...
... of radiation used to reduce side effects is not ... the standard chemotherapy in the treatment of Hodgkin,s lymphoma ... randomized study presented at the plenary session, November 1, ... Society for Radiation Oncology (ASTRO). , In addition, the ...
... 25, 2010 The Life Sciences Discovery Fund (LSDF) today ... (NASDAQ: OMER) to discover, develop, and commercialize new drugs ... generation of proceeds through partnering and the sales of ... grant would be establishment of a new non-profit initiative ...
... Patients who receive radiation before surgery for rectal cancer are ... their cancer, a new Dutch study has found. Local ... site and surrounding area -- is a major problem in ... Leiden University Medical Center in the Netherlands. This recurrence ...
Cached Medicine News:Health News:Study finds race, ethnicity impact access to care for children with frequent ear infections 2Health News:Study finds race, ethnicity impact access to care for children with frequent ear infections 3Health News:How You Handle Lack of Sleep May Be in Your Genes 2Health News:How You Handle Lack of Sleep May Be in Your Genes 3Health News:Aspirin May Help Patients Beat Prostate Cancer 2Health News:Aspirin May Help Patients Beat Prostate Cancer 3Health News:Newer, more intense chemotherapy with less radiation not more effective against Hodgkin's lymphoma 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 3Health News:Radiation Before Surgery May Prevent Return of Rectal Cancer 2
... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...
... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...
... These hygroscopic condenser humidifiers (HCH) capture ... return them in the inspired gas. Small ... provide bacteriostatic and hygroscopic benefits. Depending on ... adult or small-volume model., ,The adult ...
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
Medicine Products: